A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
A phase 3 trial testing HB1801 in HER2-positive breast cancer, active and no longer recruiting.
Overview
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT06747338, led by Shanghai JMT-Bio, and active but no longer recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer. Planned enrolment is 520 participants (estimated). The study started in 2024-12-16 and primary completion is expected in 2026-12-16. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shares HB1801, KN026, CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
Shares HB1801, CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shares CSPC Pharmaceutical Group and the tag ctgov-ingest.
- TrialPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Shares CSPC Pharmaceutical Group and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.